C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021 Nov;160(5):1751-1763. \[[PubMed: 34217681](https://pubmed.ncbi.nlm.nih.gov/34217681)\] 55. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V., MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 Feb 08;390(6):497-509. \[[PubMed: 38324483](https://pubmed.ncbi.nlm.nih.gov/38324483)\] 56. Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res. 2019 Mar 12;20(1):55. \[[PMC free article: PMC6416878](/pmc/articles/PMC6416878/)\] \[[PubMed: 30866942](https://pubmed.ncbi.nlm.nih.gov/30866942)\] 57. Mandovra NP, Vaidya PJ, Shah RS, Nighojkar AS, Chavhan VB, Lohiya A, Leuppi JD, Leuppi-Taegtmeyer A, Chhajed PN. Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease. J Clin Med. 2023 Oct 13;12(20) \[[PMC free article: PMC10606989](/pmc/articles/PMC10606989/)\] \[[PubMed: 37892651](https://pubmed.ncbi.nlm.nih.gov/37892651)\] 58. Xaubet A, Serrano-Mollar A, Ancochea J. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother. 2014 Feb;15(2):275-81. \[[PubMed: 24308635](https://pubmed.ncbi.nlm.nih.gov/24308635)\] 59. Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. \[[PMC free article: PMC6719436](/pmc/articles/PMC6719436/)\] \[[PubMed: 31016670](https://pubmed.ncbi.nlm.nih.gov/31016670)\] 60. Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019 Sep 06;20(1):205. \[[PMC free article: PMC6731623](/pmc/articles/PMC6731623/)\] \[[PubMed: 31492155](https://pubmed.ncbi.nlm.nih.gov/31492155)\] 61. Pitre T, Khalid MF, Cui S, Zhang MC, Husnudinov R, Mah J, Helmczi W, Su J, Guy B, Scallan C, Jones A, Zeraatkar D. Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulm Pharmacol Ther. 2022 Jun;73-74:102128. \[[PubMed: 35452834](https://pubmed.ncbi.nlm.nih.gov/35452834)\] 62. Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev. 2019 Sep 30;28(153) \[[PMC free article: PMC9488691](/pmc/articles/PMC9488691/)\] \[[PubMed: 31484664](https://pubmed.ncbi.nlm.nih.gov/31484664)\] 63. Chung JH, Oldham JM, Montner SM, Vij R, Adegunsoye A, Husain AN, Noth I, Lynch DA, Strek ME. CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. AJR Am J Roentgenol. 2018 May;210(5):1034-1041. \[[PubMed: 29547052](https://pubmed.ncbi.nlm.nih.gov/29547052)\] 64. Raghu G, Rochwerg B, Zhang Y, Garcia CA,